Immunitybio News - October 14, 2026

IBRX Receives Expanded FDA Approval for ANKTIVA in Bladder Cancer Treatment
IBRX

IBRX Receives Expanded FDA Approval for ANKTIVA in Bladder Cancer Treatment

ImmunityBio announced on October 14, 2026, that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for its drug, ANKTIVA®, used...
IBRX

🟢 Immunitybio is trading 5% up today after FDA expands Anktiva for papillary-only bladder cancer

Immunitybio is trading 5.05% up at $10.29 alongside the FDA’s October 14, 2026 expansion of Anktiva’s approval. - The significant company-specific milestone...